Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tnAcity: nab-Paclitaxel Combinations in TNMBC
NCT01881230Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel in triple-negative breast cancer (TNBC) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-Free Survival at 35 months. Started Sep 2013; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01881230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01881230.